Cheryl Guttman Krader
Cheryl Guttman is a medical writer based in Deerfield, Ill.
FDA approval of retinal dystrophy drug launches era of ocular gene therapy
Voretigene neparvovec-rzyl (Luxturna, Spark Therapeutics) was approved in December 2017 for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. Clinical trial results and patient selection issues for this gene therapy are discussed.
Shaffer Prize report goes down one path, but leads to another
Research aiming to elucidate the underlying factors for oxidative damage to the trabecular meshwork in glaucoma has led to studies of alterations in gene expression that may ultimately guide the development of genetic therapy for glaucoma, said Carla J. Siegfried, MD, recipient of the 2018 Shaffer Prize for Innovative Glaucoma Research.
Tumor-targeted therapy changing game for choroidal melanoma
Early results of a phase Ib/II study investigating light-activated AU-011 (Aura Biosciences) for treatment of small-medium choroidal melanoma show good safety and evidence of efficacy for this novel tumor-targeted therapy.
Travoprost implant maintains IOP-lowering benefit at 11 months
New data from a phase IIa study show that an investigational intracameral extended-release travoprost implant (ENV515, Envisia Therapeutics) provided durable IOP-lowering over a follow-up period extending to 11 months.
Lab RGCs expanding opportunities for glaucoma research
Retinal ganglion cells can be generated from patient-specific, induced pluripotent stem cells and serve as an in vitro model for pharmacologic screening and pathophysiology studies.
Trophic factor replacement targets most debilitating effects of RP
Degeneration of rods in eyes with RP leads to night vision problems and loss of rod-derived cone viability factor (RdCVF) that is necessary for cone survival. Replacing RdCVF may prevent cone degeneration and loss of central vision.
Swept-source OCT, auto-recognition enhance femtosecond laser platform
Updates to a femtosecond laser platform include a swept-source optical coherence tomography imaging system and new software that provides auto-recognition of landmarks in the eye.
Pain without stain poses diagnostic and therapeutic dilemma
Keratoneuralgia, also known as “pain without stain” is primarily a clinical diagnosis made for patients with corneal pain symptoms with minimal-to-no clinical signs and minimally, if at all, relieved by conventional dry eye treatments.
PROWL-1 provides new insights on LASIK outcomes
The Patient Reported Outcomes with LASIK-1 study shows LASIK surgery had excellent efficacy and safety, resulted in very high patient satisfaction, and was more often followed by improvements in dry eye and visual symptoms than worsening or new onset of these problems.
Targeted approach provides relief for refractory dry eye symptoms
Treatment based on the findings of a thorough history, appropriate testing, and clinical exam can be successful for bringing relief to many problem dry eye patients.

Poll